Table 2.

Comparison of clinical variables between the non-PD and PD groups.

	Non-PD group (%)	PD group (%)	P value
Sex			1.000
Male	5 (83.3)	4 (100.0)
Female	1 (16.7)	0 (0.0)
Etiology of HCC			0.679
Hepatitis B	4 (66.7)	3 (75.0)
Hepatitis C	1 (16.7)	1 (25.0)
Others	1 (16.7)	0 (0.0)
Accompanying liver cirrhosis			1.000
Yes	3 (50.0)	2 (50.0)
No	3 (50.0)	2 (50.0)
Child–Pugh class			0.400
A5	6 (100.0)	3 (75.0)
A6	0 (0.0)	1 (25.0)
Location of target lesion			0.172
Thoracic spine	3 (50.0)	0 (0.0)
Lumbar spine	3 (50.0)	2 (50.0)
Sacrum	0 (0.0)	1 (25.0)
Ilium	0 (0.0)	1 (25.0)
Radiation therapy modality			0.400
X-ray therapy	6 (0.0)	3 (75.0)
Proton therapy	0 (0.0)	1 (25.0)
Concurrent systemic treatment			0.400
Yes	0 (0.0)	1 (25.0)
No	6 (100.0)	3 (75.0)
Median αFP (ng/mL)a	10 (5.3–41,306.2)	4056.6 (3.4–156,059)	1.000

PD progressive disease, HCC hepatocellular carcinoma, αFP alpha-fetoprotein.

^aNumbers in parentheses are ranges.